| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Sulfur agent |
Is a |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Depilatory |
Is a |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Antiseborrheic agent |
Is a |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Urea topical agent |
Is a |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Contact dermatitis caused by keratolytic (disorder) |
Causative agent (attribute) |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Contact dermatitis due to keratolytic agent |
Causative agent (attribute) |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Medicinal product acting as keratolytic (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Keratolytic agent |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Medicinal product acting as antiseborrheic agent (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Salicylic acid+anthraquinone glycosides 1%/0.5% oral paint |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Urea creams and lotions |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Urea 100 mg/g cutaneous cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Product containing precisely lauromacrogol 30 milligram/1 gram and urea 50 milligram/1 gram conventional release cutaneous cream (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Product containing precisely urea 100 milligram/1 gram conventional release cutaneous lotion (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Lactic acid 50 mg/g and urea 100 mg/g cutaneous cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Dithranol+salicylic acid 0.25%/1.6% scalp gel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Product containing precisely coal tar 10 milligram/1 gram and dithranol 1.1 milligram/1 gram and salicylic acid 16 milligram/1 gram conventional release cutaneous ointment (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Salicylic acid [psoriasis] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Salicylic acid 2% ointment BP |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Zinc+salicylic acid paste BP |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Zinc+salicylic acid paste half strength |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Salicylic acid [acne] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Product containing precisely salicylic acid 20 milligram/1 gram conventional release cutaneous solution (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Salicylic acid [callosity] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Salicylic acid 20% 7.5cmx4.5cm plaster |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Salicylic acid 40% 7.5cmx4.5cm plaster |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Salicylic acid collodion BP 12% |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Lactic acid 250 mg/g and salicylic acid 250 mg/g cutaneous ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Salicylic acid+boric acid in purified talc 3%/5% powder |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Salicylic acid+zinc oxide 5%/20% dusting powder |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Salicylic acid in white soft paraffin 60%/40% ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Salicylic acid 17% liquid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Product containing precisely salicylic acid 260 milligram/1 milliliter conventional release cutaneous solution (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Salicylic acid 110 mg/g cutaneous gel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Salicylic acid+lactic acid 16.7%/16.7% paint |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Product containing precisely salicylic acid 500 milligram/1 gram conventional release cutaneous ointment (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Product containing precisely Podophyllum resin 200 milligram/1 gram and salicylic acid 250 milligram/1 gram conventional release cutaneous ointment (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Product containing precisely salicylic acid 30 milligram/1 milliliter and sulfur 50 milligram/1 milliliter conventional release cutaneous shampoo (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Product containing precisely salicylic acid 20 milligram/1 milliliter conventional release cutaneous lotion (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Salicylic acid [antifungal] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Heparinoid 2 mg/g and salicylic acid 20 mg/g transdermal cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Salicylic acid product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Product containing precisely urea 400 milligram/1 milliliter conventional release cutaneous cream (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Urea 400 mg/mL cutaneous lotion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Urea 40% |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Urea, c-14 1mic capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Urea 40g |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Salicylic acid 60 mg/g cutaneous gel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Lactic acid + salicylic acid 16.7%ww/16.7%ww |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Salicylic acid gel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Poisoning caused by keratolytic agent |
Causative agent (attribute) |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Product containing urea in topical dosage form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Lactic acid 40 mg/g and salicylic acid 120 mg/g cutaneous gel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Coal tar+salicylic acid ointment BP |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Sulfur+salicylic acid cream BP |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Sulfur+salicylic acid ointment BPC |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Product containing precisely benzoic acid 60 milligram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous cream (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Product containing salicylic acid (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Salicylic acid 20% 7.5cmx4.5cm plaster |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Salicylic acid 40% 7.5cmx4.5cm plaster |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Product containing coal tar and salicylic acid and sulfur (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Coal tar 12%/sulfur 4%/salicylic acid 2% ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Betamethasone+salicylic acid 0.05/3% scalp application |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Product containing betamethasone and salicylic acid (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Product containing benzoic acid and salicylic acid (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Product containing salicylic acid and sulfur (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Product containing salicylic acid and zinc oxide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Product containing lauromacrogol and urea (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Product containing dithranol and salicylic acid (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Product containing desoximetasone and salicylic acid (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
| Product containing camphor and salicylic acid (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent kératolytique |
Inferred relationship |
Some |
|
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]